Answers are grounded in this paper and cite their sources.
The aim of this study was to evaluate the n-3 fatty acid supplementation effects in breast cancer patients. Methods: it was a prospective longitudinal study performed in breast cancer patients supplemented with fish oil during 8 weeks in neoadjuvant AC-T regimen. Anthropometric, Bioelectrical impedance (BIA) ((Lean Body Mass (LBM), and Phase Angle (PA)), food consumption, nutritional impact symptoms (NIS), metabolic and inflammatory profile were evaluated for 2 months. Results: supplemented patients presented weight gain of 1.4 kg, representing 1.8% of body weight. LBM was 42.3 Kg and PA 6.1º. Nausea, diarrhea and anorexia were the main NIS with reduction in incidence with the supplementation, but xerostomia and heartburn had increase. There was significant drop in hemoglobin values to 12.3 mg/dL, metabolic parameters and nutritional prognosis (CRP/albumin ratio) were not altered. Cytokines levels of TNF-? and interleukin-6 did not change, however interleukin-2 have shown significant increasing. Conclusion: Body weight gain was noticed in breast cancer patients, independent of food consumption. Fish oil supplementation during neoadjuvant chemotherapy was able to reduce NIS incidence, but not avoiding the decrease of hemoglobin levels, but it keeps the maintenance of pro-inflammatory parameters, except for increased the cytokine IL-2.
No takes yet. Share an insight, caveat, or question.
Rosset et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: